This hasn’t been a great year to be a foreign drug maker in China, as a developing government anti-bribery crackdown has resulted in arrests and the prospect of monster fines. But assuming they can weather this storm, China is a pharmaceutical firm’s dream market, with an aging, increasingly affluent population that is falling prey to the chronic illnesses of the developed world.
Read Full Article »
